摘要
Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma.Case.We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen.She achieved a complete response and remains relap se-free 21months after her last dose of chemotherapy.Conclusion.The literaturesuggests that paclitaxel contribut es significantly to the treatment of choriocarcinoma and it s use should be explored further.This is the first case report formally reporting its combinationwith cisplatin.
Background.Both preclinical data a nd case reports sup-port the use of taxanes for high-risk metastatic choriocar-cinoma.Case.We report the case of a 31-year-old with metastatic choriocarcinoma who req uired 3rd-line treatment with a paclitaxel-cispaltin-based regimen.She achieved a complete response and remains relap se-free 21months after her last dose of chemotherapy.Conclusion.The literaturesuggests that paclitaxel contribut es significantly to the treatment of choriocarcinoma and it s use should be explored further.This is the first case report formally reporting its combinationwith cisplatin.
